Known targets — ChEMBL curated mechanism
ADRA2AADRA2BADRA2CADRB2AGTR1AVPR1AAVPR1BAVPR2BDKRB2CALCRCHRNA3CHRNB4ESR1ESR2GHSRGNRHRGSC1HSPA8MALT1MC1RMC4RNOS1NOS2NOS3OPRK1OXTRRAMP1RAMP2RAMP3SCN5ASSTR1SSTR2SSTR3SSTR4SSTR5dacAdacBdacCfolPftsImrcAmrcBmrdArplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Tetrabuthylammonium. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC22A1 | O15245 | 3/20 | 0.60 |
| ▸ | SLC22A2 | O15244 | 1/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.48 |
| ▸ | TP53 | P04637 | 1/20 | 0.48 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.48 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.48 |
| ▸ | TSHR | P16473 | 1/20 | 0.48 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.48 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.48 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.48 |
| ▸ | CES2 | O00748 | 4/20 | 0.46 |
| ▸ | CES1 | P23141 | 4/20 | 0.46 |
| ▸ | DNM1 | Q05193 | 3/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Tetrabuthylammonium SCHEMBL17180398 | 1.00 | SLC22A1 (0.60) | SLC22A1SLC22A2ALDH1A1TP53CYP3A4 | |
| Tetrabuthylammonium SCHEMBL5202551 | 0.98 | SLC22A1 (0.57) | SLC22A1SLC22A2ALDH1A1TP53CYP3A4 | |
| Tetrabuthylammonium SCHEMBL5202534 | 0.98 | SLC22A1 (0.57) | SLC22A1SLC22A2ALDH1A1TP53CYP3A4 | |
| Tetrabuthylammonium SCHEMBL5202538 | 0.98 | SLC22A1 (0.57) | SLC22A1SLC22A2ALDH1A1TP53CYP3A4 | |
| Tetrabuthylammonium SCHEMBL9118025 | 0.97 | SLC22A1 (0.63) | SLC22A1SLC22A2ALDH1A1TP53CYP3A4 | |
| Tetrabuthylammonium SCHEMBL9119754 | 0.97 | SLC22A1 (0.63) | SLC22A1SLC22A2ALDH1A1TP53CYP3A4 | |
| Tetrabuthylammonium SCHEMBL29563334 | 0.97 | SLC22A1 (0.63) | SLC22A1SLC22A2ALDH1A1TP53CYP3A4 | |
| Tetrabuthylammonium SCHEMBL36122 | 0.97 | SLC22A1 (0.63) | SLC22A1SLC22A2ALDH1A1TP53CYP3A4 | |
| Tetrabuthylammonium SCHEMBL27346864 | 0.95 | SLC22A1 (0.60) | SLC22A1SLC22A2ALDH1A1TP53CYP3A4 | |
| Tetrabuthylammonium SCHEMBL27961179 | 0.95 | SLC22A1 (0.60) | SLC22A1SLC22A2ALDH1A1TP53CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 41 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118307609-A | Synthesis method of natural Toll-like Receptor 2 agonist CaLGL-1 | 兰州大学 | 2024-07-09 | — | — | CN | claimed |
| WO-2024140934-A1 | PREPARATION METHOD FOR LINKER-DRUG CONJUGATE AND INTERMEDIATE THEREOF | 上海复旦张江生物医药股份有限公司 | 2024-07-04 | — | — | WO | claimed |
| CN-116217655-A | Preparation method of intermediate of linker drug conjugate | 上海复旦张江生物医药股份有限公司 | 2023-06-06 | — | — | CN | claimed |
| CN-116178386-A | Preparation method of linker drug conjugate and intermediate thereof | 上海复旦张江生物医药股份有限公司 | 2023-05-30 | — | — | CN | claimed |
| CN-115385926-A | Preparation method of connection base drug conjugate and intermediate thereof | 上海复旦张江生物医药股份有限公司 | 2022-11-25 | — | — | CN | claimed |
| CN-115215921-A | Preparation method of connection base drug conjugate and intermediate thereof | 上海复旦张江生物医药股份有限公司 | 2022-10-21 | — | — | CN | claimed |
| WO-2024140934-A1 | PREPARATION METHOD FOR LINKER-DRUG CONJUGATE AND INTERMEDIATE THEREOF | 上海复旦张江生物医药股份有限公司 | 2024-07-04 | — | — | WO | disclosed |
| CN-116217655-A | Preparation method of intermediate of linker drug conjugate | 上海复旦张江生物医药股份有限公司 | 2023-06-06 | — | — | CN | disclosed |
| CN-116178386-A | Preparation method of linker drug conjugate and intermediate thereof | 上海复旦张江生物医药股份有限公司 | 2023-05-30 | — | — | CN | disclosed |
| CN-115385926-A | Preparation method of connection base drug conjugate and intermediate thereof | 上海复旦张江生物医药股份有限公司 | 2022-11-25 | — | — | CN | disclosed |
| CN-115215921-A | Preparation method of connection base drug conjugate and intermediate thereof | 上海复旦张江生物医药股份有限公司 | 2022-10-21 | — | — | CN | disclosed |
| US-10730904-B2 | Method for liquid-phase synthesis of nucleic acid | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2020-08-04 | — | — | US | disclosed |
| EP-2921499-B1 | METHOD FOR LIQUID-PHASE SYNTHESIS OF NUCLEIC ACIDS | TAKEDA PHARMACEUTICALS CO (JP) | 2020-01-22 | — | — | EP | disclosed |
| US-5300638-A | Reacting imine derivative of threonine with an acetyl halide in the presence of a base; preferential | BRISTOL-MYERS SQUIBB COMPANY (US) | 1994-04-05 | — | — | US | disclosed |
| EP-0321186-B1 | 6-(Substituted methylene)penems | BEECHAM GROUP PLC (GB) | 1994-03-02 | — | — | EP | disclosed |
| US-5276217-A | Anticarcinogenic, analog of sarcophytol A, carbocyclic compound with 6-14 ring carbons | UNIVERSITY OF HAWAII (US) | 1994-01-04 | — | — | US | disclosed |
| WO-1993018651-A1 | CYCLIC ANTI-TUMOR PROMOTER COMPOUNDS, COMPOSITIONS AND METHODS FOR PRODUCTION AND USE | UNIVERSITY OF HAWAII (US) | 1993-09-30 | — | — | WO | disclosed |
| EP-0525589-A1 | Asymmetric synthesis of taxol side chain | Bristol-Myers Squibb Company (US) | 1993-02-03 | — | — | EP | disclosed |
| US-4923856-A | Penem compounds | BEECHAM GROUP P.L.C. (GB) | 1990-05-08 | — | — | US | disclosed |
| EP-0321186-A1 | 6-(Substituted methylene)penems | BEECHAM GROUP PLC (GB) | 1989-06-21 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10730904-B2 | Method for liquid-phase synthesis of nucleic acid | RNGTT, POLR2H, POLR2E | SLC22A1 2383/4885SLC22A2 2798/4885ALDH1A1 1416/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.